Evaluation of clinical effect and safety of desloratadine in treating allergic rhinitis

AIM: To evaluate the effect and safety of delortadine in treating allergic rhinitis. METHODS: A multi-center randomized and double-blind clinical trial was used. Two hundred and forty patients were divided into two groups and 224 patients finished the trial in the end. The desloratadine group of 114 patients (M 55,F 59;age(40±s 7) a) took desloratadine tablet (5 mg),po,qd. The loratadinum group of 110 patients (M 45,F 65;age(39±7) a ) took loratadinum tablet 10 mg,po,qd. The period of treatment of both groups was 2 wk. RESULTS: After 2 wk treatment, the notable effective patients and the effective rate of desloratadine were 46 and (92.1 %), those of loratadine were 32 and (88.2 %). There was no difference between two groups (P(0.05)). The adverse reaction rate was (8.3 %) and (15.0 %), respectively. There was no signficant difference between two groups (P(0.05)). CONCLUSION: Desloratadine in treating allergic rhinitis is safe and effective with mild adverse reactions.